PT3277717T - Uma nova forma de il33, formas mutadas de il33, anticorpos, ensaios e métodos de uso dos mesmos - Google Patents

Uma nova forma de il33, formas mutadas de il33, anticorpos, ensaios e métodos de uso dos mesmos

Info

Publication number
PT3277717T
PT3277717T PT167123538T PT16712353T PT3277717T PT 3277717 T PT3277717 T PT 3277717T PT 167123538 T PT167123538 T PT 167123538T PT 16712353 T PT16712353 T PT 16712353T PT 3277717 T PT3277717 T PT 3277717T
Authority
PT
Portugal
Prior art keywords
assays
antibodies
novel
methods
same
Prior art date
Application number
PT167123538T
Other languages
English (en)
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of PT3277717T publication Critical patent/PT3277717T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
PT167123538T 2015-03-31 2016-03-30 Uma nova forma de il33, formas mutadas de il33, anticorpos, ensaios e métodos de uso dos mesmos PT3277717T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562140913P 2015-03-31 2015-03-31

Publications (1)

Publication Number Publication Date
PT3277717T true PT3277717T (pt) 2021-02-01

Family

ID=55640748

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167123538T PT3277717T (pt) 2015-03-31 2016-03-30 Uma nova forma de il33, formas mutadas de il33, anticorpos, ensaios e métodos de uso dos mesmos

Country Status (30)

Country Link
US (3) US10668150B2 (pt)
EP (2) EP3733701A1 (pt)
JP (3) JP6862351B2 (pt)
KR (1) KR102261618B1 (pt)
CN (1) CN108064236B (pt)
AU (3) AU2016239331C1 (pt)
BR (1) BR112017020955A2 (pt)
CA (1) CA2982400C (pt)
CL (2) CL2017002433A1 (pt)
CO (1) CO2017010753A2 (pt)
CY (1) CY1123925T1 (pt)
DK (1) DK3277717T3 (pt)
ES (1) ES2886114T3 (pt)
HK (1) HK1250728A1 (pt)
HR (1) HRP20210096T1 (pt)
HU (1) HUE053097T2 (pt)
IL (2) IL254551A0 (pt)
LT (1) LT3277717T (pt)
MX (1) MX2017012616A (pt)
MY (1) MY190209A (pt)
NZ (1) NZ736026A (pt)
PL (1) PL3277717T3 (pt)
PT (1) PT3277717T (pt)
RS (1) RS61438B1 (pt)
RU (1) RU2736299C2 (pt)
SG (1) SG11201707593UA (pt)
SI (1) SI3277717T1 (pt)
TW (1) TWI721973B (pt)
WO (1) WO2016156440A1 (pt)
ZA (1) ZA201707355B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015099175A1 (ja) 2013-12-26 2015-07-02 田辺三菱製薬株式会社 ヒト抗ｉｌ－３３中和モノクローナル抗体
US20160168640A1 (en) 2014-11-10 2016-06-16 Genentech, Inc. Therapeutic and diagnostic methods for il-33-mediated disorders
EP3218403B1 (en) 2014-11-10 2020-05-13 F.Hoffmann-La Roche Ag Anti-interleukin-33 antibodies and uses thereof
SG11201808693WA (en) 2016-04-27 2018-11-29 Pfizer Anti-il-33 antibodies, compositions, methods and uses thereof
JOP20190093A1 (ar) 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
AR110414A1 (es) * 2016-12-21 2019-03-27 Cephalon Inc Anticuerpos que se unen específicamente a il-15 humana y usos de estos
EP3957752A3 (en) 2017-04-13 2022-06-15 Regeneron Pharmaceuticals, Inc. Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
US11248054B2 (en) 2017-06-12 2022-02-15 Bluefin Biomedicine, Inc. Anti-IL1RAP antibodies and antibody drug conjugates
MX2020002086A (es) 2017-08-31 2020-10-28 Mitsubishi Tanabe Pharma Corp Agente terapeutico que contiene antagonista de il-33 para endometriosis.
CN107973849B (zh) * 2017-11-30 2020-07-28 畜科生物工程有限公司 一种用于增强猪疫苗免疫效果的蛋白质及其应用
WO2019183375A1 (en) * 2018-03-22 2019-09-26 Eureka Therapeutics, Inc. Antibody agents specifically recognizing monocarboxylate transporter 4 and uses thereof
IL307286A (en) 2018-04-11 2023-11-01 Regeneron Pharma Methods and preparations for quantification of IL-33
JP7407723B2 (ja) * 2018-09-14 2024-01-04 田辺三菱製薬株式会社 ヒト抗ｉｌ－３３モノクローナル抗体含有医薬用組成物
CN111434687B (zh) * 2019-01-15 2022-03-11 南京赛新生物科技有限公司 一种抗体及其应用
CN111434680B (zh) * 2019-01-15 2021-11-23 南京赛新生物科技有限公司 一种与il33相关疾病的抗原表位肽及其应用
CN112300265B (zh) * 2019-07-29 2022-09-27 百奥赛图(北京)医药科技股份有限公司 Il33基因人源化的非人动物的构建方法和应用
CN110567861B (zh) * 2019-09-09 2021-12-21 浙江普罗亭健康科技有限公司 基于质谱流式检测技术筛查具有免疫原性抗原肽的试剂盒及检测方法
CN114901361A (zh) 2019-11-04 2022-08-12 免疫医疗有限公司 使用il-33拮抗剂的方法
WO2021089559A1 (en) 2019-11-04 2021-05-14 Medimmune Limited Anti il-33 therapeutic agent fpr treating renal disorders
WO2021180858A1 (en) 2020-03-13 2021-09-16 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
AU2021236306A1 (en) 2020-03-13 2022-09-15 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
AU2021253117A1 (en) 2020-04-06 2022-12-01 Medimmune Limited Treating acute respiratory distress syndrome with IL-33 axis binding antagonists
KR20230010239A (ko) 2020-05-11 2023-01-18 메디뮨 리미티드 항-il-33 항체의 제형물
CN111378037B (zh) * 2020-06-01 2020-09-01 南京诺艾新生物技术有限公司 一种抗hIL-33人源化单抗及其应用
EP4295154A1 (en) 2021-02-18 2023-12-27 F. Hoffmann-La Roche AG Method for resolving complex, multistep antibody interactions
CN113234157B (zh) * 2021-07-09 2021-09-21 上海普铭生物科技有限公司 亲和力成熟的人源化抗人il-33单克隆抗体及其应用
EP4244252A1 (en) 2021-08-27 2023-09-20 MedImmune Limited Treatment of chronic obstructive pulmonary disease with an anti-interleukin-33 antibody
WO2023086807A1 (en) * 2021-11-10 2023-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
WO2024038186A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Treatment of acute respiratory failure
WO2024038185A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Method of selecting patients for treatment with an il-33 axis antagonist
WO2024038187A1 (en) 2022-08-19 2024-02-22 Medimmune Limited Assay for detection of il-33
WO2024042212A1 (en) 2022-08-26 2024-02-29 Medimmune Limited Treatment of asthma with an anti-interleukin-33 antibody

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
CA1319120C (en) 1985-04-01 1993-06-15 John Henry Kenten Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5136964A (en) 1989-01-19 1992-08-11 Arnold J. Cook Warning device for windsurfing craft
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992005793A1 (en) 1990-10-05 1992-04-16 Medarex, Inc. Targeted immunostimulation with bispecific reagents
ATE160379T1 (de) 1990-10-29 1997-12-15 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
AU660297B2 (en) 1990-11-09 1995-06-22 Stephen D. Gillies Cytokine immunoconjugates
AP257A (en) 1991-04-26 1993-06-03 Surface Active Ltd A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy.
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
ATE239506T1 (de) 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
US6706484B1 (en) 1995-08-18 2004-03-16 Morphosys Ag Protein/(poly)peptide libraries
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
ES2353268T3 (es) 1999-07-02 2011-02-28 Morphosys Ag Generacion de elementos de union especifica que se unen a (poli)peptidos codificados por fragmentos de adn genomico o est.
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
WO2001066754A1 (en) 2000-03-03 2001-09-13 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
DE60126130T2 (de) 2000-11-17 2007-10-18 The University Of Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
UA115964C2 (uk) 2006-09-08 2018-01-25 Еббві Айрленд Анлімітед Компані Інтерлейкін-13-зв'язувальний білок
WO2008137552A2 (en) 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof
WO2008144610A1 (en) * 2007-05-18 2008-11-27 Medimmune, Llc Il-33 in inflammatory disease
WO2009055074A2 (en) 2007-10-25 2009-04-30 Wyeth Erbb2 binding proteins and use thereof
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
MY166429A (en) * 2010-11-17 2018-06-26 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
AR091069A1 (es) * 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها

Also Published As

Publication number Publication date
AU2019250213B2 (en) 2021-12-02
EP3277717A1 (en) 2018-02-07
RU2017134909A3 (pt) 2019-12-23
IL280045A (en) 2021-03-01
IL254551A0 (en) 2017-11-30
US20240016929A1 (en) 2024-01-18
CY1123925T1 (el) 2022-05-27
AU2021257881A1 (en) 2021-11-18
ZA201707355B (en) 2022-06-29
US10668150B2 (en) 2020-06-02
HUE053097T2 (hu) 2021-06-28
CA2982400C (en) 2023-10-24
CL2020002269A1 (es) 2021-01-22
PL3277717T3 (pl) 2021-05-31
RU2017134909A (ru) 2019-03-28
CA2982400A1 (en) 2016-10-06
TW201704259A (zh) 2017-02-01
US20200353078A1 (en) 2020-11-12
TWI721973B (zh) 2021-03-21
AU2021257881B2 (en) 2022-02-17
IL280045B (en) 2021-09-30
BR112017020955A2 (pt) 2018-07-10
CN108064236A (zh) 2018-05-22
EP3277717B1 (en) 2020-11-18
JP6862351B2 (ja) 2021-04-21
MY190209A (en) 2022-04-05
SI3277717T1 (sl) 2021-03-31
KR20170132811A (ko) 2017-12-04
ES2886114T3 (es) 2021-12-16
JP2018516853A (ja) 2018-06-28
RU2736299C2 (ru) 2020-11-13
CN108064236B (zh) 2021-12-10
JP2021038226A (ja) 2021-03-11
HRP20210096T1 (hr) 2021-03-05
SG11201707593UA (en) 2017-10-30
NZ736026A (en) 2023-02-24
MX2017012616A (es) 2018-04-10
LT3277717T (lt) 2021-08-10
CO2017010753A2 (es) 2018-03-20
AU2019250213A1 (en) 2019-11-07
WO2016156440A1 (en) 2016-10-06
EP3733701A1 (en) 2020-11-04
DK3277717T3 (da) 2021-02-01
RS61438B1 (sr) 2021-03-31
CL2017002433A1 (es) 2018-05-04
US11738081B2 (en) 2023-08-29
AU2016239331B2 (en) 2019-07-25
JP2024001166A (ja) 2024-01-09
US20180207265A1 (en) 2018-07-26
AU2016239331C1 (en) 2020-01-30
HK1250728A1 (zh) 2019-01-11
AU2016239331A1 (en) 2017-10-26
KR102261618B1 (ko) 2021-06-04

Similar Documents

Publication Publication Date Title
IL280045B (en) Novel form of il33, mutant forms of il33, antibodies, assays and methods for their use
IL264654B1 (en) Anti-tigit antibodies, anti-pvrig antibodies and their combinations
IL264159A (en) Anti-tim-3 antibodies
HK1243104A1 (zh) 抗fgfr2/3抗體及其使用方法
IL304772A (en) Antibodies, uses and methods
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
GB201403875D0 (en) Novel antibodies and uses thereof
GB201413913D0 (en) Novel antibodies and uses thereof
IL252430A0 (en) Antibodies, uses and methods
GB201610044D0 (en) Antibodies
GB201603291D0 (en) Antibodies
PT3178929T (pt) Novo anticorpo anti-ig(beta) humana
IL264262A (en) Antibodies against interleukin 22 receptors
GB201616699D0 (en) Antibodies
IL263406B1 (en) Anti-tnfrs25 antibodies
GB201622197D0 (en) Antibodies
GB201620414D0 (en) Antibodies
GB201615224D0 (en) Antibodies
GB201613158D0 (en) Antibodies
GB201612437D0 (en) Anti-lag-3 antibodies
TH1701000696B (th) แผ่นโลหะที่ถูกเคลือบผิว, วิธีสำหรับการผลิตสิ่งเดียวกันนั้น, และวัสดุก่อสร้างภายนอก
GB201401812D0 (en) Enzyme cascade immunoassay